A Study DHP107, a Novel Oral Paclitaxel Formulation, in Patients With Advanced Solid Tumours or Gastric Cancer
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
A study of DHP107, a novel oral paclitaxel formulation, to determine maximum tolerated dose
and recommended dose for phase II trial in patients with advanced solid cancer and explore
efficacy of DHP107 in patients with gastric cancer